Bladder transitional cell carcinoma stage I is an early form of bladder cancer where malignant cells have begun growing into the layer beneath the bladder’s inner lining, but have not yet reached the deeper muscle wall. Treatment at this stage focuses on removing the tumor completely, preventing cancer from returning, and stopping it from advancing to more serious stages that could threaten survival and require more aggressive interventions.

Understanding Treatment Goals for Early Bladder Cancer

When someone receives a diagnosis of stage I bladder transitional cell carcinoma, the good news is that the cancer has been caught at a relatively early point. At this stage, the disease has grown beyond the innermost layer of the bladder lining into a layer of connective tissue called the lamina propria, but it hasn’t invaded the bladder’s muscle wall yet. This distinction matters enormously because cancers that remain in these outer layers respond much better to treatment than those that have penetrated deeper.^[3]

Treatment goals for stage I bladder cancer center on three main objectives. First, doctors aim to remove all visible cancer from the bladder. Second, they work to prevent the disease from coming back, which is a significant concern because this type of cancer has a strong tendency to recur even after successful treatment. Third, they try to stop the cancer from progressing to a more advanced stage, where it could invade the muscle layer and become much harder to control. The specific approach depends on factors like the tumor’s grade (how abnormal the cells look under a microscope), the depth of invasion into the lamina propria, the number of tumors present, and the patient’s overall health.^[3][8]

Medical societies have established standard treatment protocols based on years of research and clinical experience. At the same time, researchers continue exploring new therapies through clinical trials, testing innovative approaches that might offer better outcomes or fewer side effects than current treatments. Understanding both established and experimental options helps patients and their doctors make informed decisions about care.

Standard Treatment Approaches

Surgical Removal: The First Line of Defense

The initial treatment for stage I bladder cancer almost always involves a surgical procedure called transurethral resection (TUR) with fulguration. During this operation, a surgeon inserts a special instrument called a cystoscope through the urethra (the tube that carries urine out of the body) and into the bladder. The cystoscope has a light, camera, and cutting tools that allow the surgeon to see the tumor and remove it without making any cuts in the abdomen.^[8][9]

The surgeon carefully cuts away all visible tumor tissue, taking samples from different depths to ensure they remove everything and can accurately determine how far the cancer has spread. Fulguration refers to the use of electrical current to burn away any remaining cancer cells and seal blood vessels to prevent bleeding. This procedure typically requires general or spinal anesthesia, and most patients can go home the same day or after a brief hospital stay.^[12]

Sometimes doctors recommend a second TUR procedure, especially if the first surgery didn’t include a sample from the muscle layer or if there’s concern that not all cancer was removed. This repeat surgery, usually performed several weeks after the first, helps ensure complete tumor removal and provides better information about the cancer’s stage. If this second look finds that cancer has actually invaded the muscle, the treatment plan changes significantly because the disease would then be considered more advanced than stage I.^[8][13]

Intravesical Therapy: Medication Delivered Directly to the Bladder

Because stage I bladder cancer has a high likelihood of returning even after complete surgical removal, most patients receive additional treatment called intravesical therapy. This approach involves placing medication directly into the bladder through a catheter (a thin tube inserted through the urethra). By delivering treatment right where the cancer started, doctors can attack any remaining cancer cells while minimizing side effects throughout the rest of the body.^[8][19]

Two main types of intravesical therapy are used: chemotherapy and immunotherapy. Chemotherapy drugs commonly used include mitomycin and gemcitabine. These medications kill rapidly dividing cancer cells. Many patients receive a single dose of chemotherapy immediately after tumor removal, sometimes during the same procedure, to destroy any cancer cells that might have been released during surgery. This single early treatment can significantly reduce the chance of cancer returning.^[8][12]

The other major intravesical treatment is BCG (Bacillus Calmette-Guérin), a type of immunotherapy. BCG is actually a weakened form of bacteria related to tuberculosis. When placed in the bladder, it triggers a strong immune response that helps the body’s natural defenses recognize and destroy cancer cells. BCG has proven particularly effective for preventing cancer recurrence and progression in stage I disease, especially for high-grade tumors or those that penetrate deeply into the lamina propria.^[8][9]

Intravesical therapy typically follows a specific schedule. Patients usually receive treatments once a week for six weeks. This initial course is often followed by maintenance therapy, where treatments continue at less frequent intervals for one to three years, depending on the cancer’s characteristics. During each treatment session, the medication remains in the bladder for about two hours before the patient urinates it out.^[8][19]

Managing Side Effects of Standard Treatment

The surgical removal of bladder tumors is generally well-tolerated, but some patients experience temporary side effects. Blood in the urine for a few days after surgery is common and expected. Some people feel a burning sensation or increased urgency to urinate for a week or two as the bladder heals. Drinking plenty of water helps flush the bladder and promotes healing. Serious complications from TUR are uncommon but can include excessive bleeding, infection, or in rare cases, a hole (perforation) in the bladder wall.^[9]

Intravesical chemotherapy causes relatively mild side effects for most patients. Bladder irritation is the most common complaint, leading to symptoms like frequent urination, urgency, and a burning feeling during urination. These symptoms typically appear within a few hours of treatment and resolve within a day or two. Some people develop a skin rash if the chemotherapy leaks onto the skin around the urethra, so careful catheter placement and technique are important.^[12]

BCG immunotherapy can cause more noticeable side effects because it provokes an immune response. Many patients experience bladder irritation symptoms similar to those from chemotherapy, but often more pronounced. Some people develop flu-like symptoms including fever, fatigue, and body aches, usually beginning a few hours after treatment and lasting a day or two. These symptoms indicate the immune system is responding to the treatment. More serious side effects, though uncommon, can include a severe infection requiring antibiotics, or in rare cases, a systemic BCG infection that needs specialized treatment. Patients receiving BCG should report persistent fever, severe flu-like symptoms, or signs of infection to their doctor immediately.^[9][12]

Duration and Follow-up

The initial surgery to remove tumors takes place as soon as possible after diagnosis. The six-week course of intravesical therapy typically begins a few weeks after surgery, once the bladder has healed. For patients receiving maintenance BCG therapy, treatments may continue for one to three years, with the specific duration depending on whether the cancer is classified as intermediate-risk or high-risk for recurrence.^[8][19]

After completing initial treatment, patients need regular follow-up appointments because bladder cancer frequently returns. Follow-up typically includes cystoscopy examinations, where a doctor looks inside the bladder with a camera to check for new tumors, along with urine tests to detect cancer cells. These examinations are scheduled frequently at first (often every three to six months) and may become less frequent over time if no cancer recurs. Some patients also need periodic imaging tests such as CT scans to check the kidneys and ureters.^[16][17]

Treatment Options in Clinical Trials

What Are Clinical Trials and Why They Matter

Clinical trials are research studies that test new treatments or new ways of using existing treatments. For bladder cancer, researchers constantly work to find therapies that work better than current options, cause fewer side effects, or both. Participation in clinical trials gives some patients access to promising new treatments before they become widely available. Clinical trials also help advance medical knowledge that benefits future patients.^[8]

Clinical trials proceed through several phases, each designed to answer specific questions. Phase I trials test whether a new treatment is safe, determine the appropriate dose, and identify side effects. These studies usually involve a small number of patients. Phase II trials examine whether the treatment actually works against the cancer and continue monitoring safety in a larger group. Phase III trials compare the new treatment directly against the current standard treatment to determine which works better. These large studies provide the strongest evidence about whether a new therapy should replace existing treatments.^[8]

Innovative Approaches Being Studied

Researchers are exploring several innovative treatment approaches for stage I bladder cancer in clinical trials. Much of this research focuses on patients whose cancer returns after initial treatment or who cannot tolerate standard intravesical therapy, particularly BCG. However, some trials also investigate new treatments as alternatives to standard therapy even for newly diagnosed patients.

One area of active research involves different immunotherapy agents. While BCG has been the standard immunotherapy for bladder cancer for decades, scientists are testing newer immunotherapy drugs called checkpoint inhibitors. These medications work by removing the brakes on the immune system, allowing it to attack cancer cells more effectively. Some checkpoint inhibitors have already proven effective for advanced bladder cancer and are now being studied for earlier stages. These drugs are typically given through an intravenous infusion rather than directly into the bladder.^[8]

Another promising direction involves combining different types of treatment. For example, some trials test whether using chemotherapy and immunotherapy together works better than either treatment alone. The idea is that chemotherapy might kill cancer cells in one way while immunotherapy attacks them through a completely different mechanism, potentially providing better cancer control. Researchers carefully monitor these combination approaches to ensure the treatments don’t produce unacceptable side effects when used together.

Gene therapy represents another frontier in bladder cancer research. Scientists are exploring ways to deliver specific genes into bladder cells that could help fight cancer or make cancer cells more vulnerable to other treatments. While this approach is still in early research stages for bladder cancer, it holds promise for the future.

Targeted therapies designed to attack specific molecular abnormalities in cancer cells are also under investigation. Bladder cancer cells often have particular genetic changes that make them grow and spread. Researchers are developing drugs that specifically target these changes while leaving normal cells relatively unharmed. This precision approach could potentially provide effective treatment with fewer side effects than traditional chemotherapy.

Practical Considerations for Clinical Trial Participation

Clinical trials for bladder cancer take place at major cancer centers and academic hospitals throughout the United States, Europe, and other regions. Not every patient qualifies for every trial because studies have specific eligibility requirements. These requirements might include factors like the exact stage and grade of cancer, previous treatments received, overall health status, and other medical conditions. Doctors can help patients determine whether any available trials might be appropriate for their situation.^[8]

Participating in a clinical trial doesn’t mean giving up standard treatment if the experimental approach doesn’t work. Patients in trials receive careful monitoring, and if the new treatment isn’t working or causes unacceptable side effects, they can stop the trial and pursue other options. Most trials also ensure that participants receive at least the standard level of care, so they’re not receiving less treatment than they would outside the trial.

Most common treatment methods

• Surgical treatment
  • Transurethral resection (TUR) with fulguration removes tumors through the urethra using a cystoscope, avoiding external incisions
  • May require a repeat procedure to ensure complete removal and accurate staging
  • Typically performed under general or spinal anesthesia with same-day or brief hospital stay
• Intravesical chemotherapy
  • Mitomycin delivered directly into the bladder through a catheter to kill cancer cells
  • Gemcitabine used as an alternative chemotherapy agent for bladder instillation
  • Often given as a single dose immediately after tumor removal, followed by weekly treatments
• Intravesical immunotherapy
  • BCG (Bacillus Calmette-Guérin) stimulates the immune system to attack cancer cells
  • Typically given weekly for six weeks, followed by maintenance therapy for one to three years
  • Particularly effective for high-grade tumors and preventing cancer progression
• Surveillance and monitoring
  • Regular cystoscopy examinations to inspect the bladder for cancer recurrence
  • Urine tests to detect cancer cells
  • Scheduled frequently at first, becoming less frequent over time without recurrence